268 related articles for article (PubMed ID: 22179399)
1. Clinical utility of cytomegalovirus cell-mediated immunity in transplant recipients with cytomegalovirus viremia.
Lisboa LF; Kumar D; Wilson LE; Humar A
Transplantation; 2012 Jan; 93(2):195-200. PubMed ID: 22179399
[TBL] [Abstract][Full Text] [Related]
2. [Monitoring of cytomegalovirus-specific CD4+ and CD8+ T cell responses by cytokine flow cytometry in renal transplant recipients].
Kılınçkaya Doğan H; Mutlu E; Köksoy S; Yılmaz VT; Koçak H; Çolak D; Mutlu D; Günseren F; Dinçkan A; Aliosmanoğlu İ; Süleymanlar G; Gültekin M
Mikrobiyol Bul; 2016 Apr; 50(2):224-35. PubMed ID: 27175495
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of cytomegalovirus (CMV)-specific T cell immune reconstitution revealed that baseline antiviral immunity, prophylaxis, or preemptive therapy but not antithymocyte globulin treatment contribute to CMV-specific T cell reconstitution in kidney transplant recipients.
Abate D; Saldan A; Fiscon M; Cofano S; Paciolla A; Furian L; Ekser B; Biasolo MA; Cusinato R; Mengoli C; Bonfante L; Rossi B; Rigotti P; Sgarabotto D; Barzon L; Palù G
J Infect Dis; 2010 Aug; 202(4):585-94. PubMed ID: 20594105
[TBL] [Abstract][Full Text] [Related]
4. QuantiFERON®-CMV assay for the assessment of cytomegalovirus cell-mediated immunity.
Giulieri S; Manuel O
Expert Rev Mol Diagn; 2011 Jan; 11(1):17-25. PubMed ID: 21171917
[TBL] [Abstract][Full Text] [Related]
5. Monitoring of CMV-Specific Cell-Mediated Immunity in Kidney Transplant Recipients With a High Risk of CMV Disease (D+/R-): A Case Series.
Andreani M; Albano L; Benzaken S; Cassuto E; Jeribi A; Caramella A; Giordanengo V; Bernard G; Esnault V; Seitz-Polski B
Transplant Proc; 2020; 52(1):204-211. PubMed ID: 31889538
[TBL] [Abstract][Full Text] [Related]
6. Kinetics of interferon-gamma producing cytomegalovirus (CMV)-specific CD4+ and CD8+ T lymphocytes and the risk of subsequent CMV viremia after allogeneic hematopoietic stem cell transplantation.
Eid AJ; Brown RA; Hogan WJ; Lahr BD; Eckel-Passow JE; Litzow MR; Razonable RR
Transpl Infect Dis; 2009 Dec; 11(6):519-28. PubMed ID: 19744286
[TBL] [Abstract][Full Text] [Related]
7. Quantiferon-CMV test in prediction of cytomegalovirus infection after kidney transplantation.
Lochmanova A; Lochman I; Tomaskova H; Marsalkova P; Raszka J; Mrazek J; Dedochova J; Martinek A; Brozmanova H; Grundmann M
Transplant Proc; 2010 Nov; 42(9):3574-7. PubMed ID: 21094818
[TBL] [Abstract][Full Text] [Related]
8. CMV-specific T-cell immunity, viral load, and clinical outcome in seropositive renal transplant recipients: a pilot study.
Sund F; Lidehäll AK; Claesson K; Foss A; Tötterman TH; Korsgren O; Eriksson BM
Clin Transplant; 2010; 24(3):401-9. PubMed ID: 19222507
[TBL] [Abstract][Full Text] [Related]
9. T-cell immunity to subclinical cytomegalovirus infection reduces cardiac allograft disease.
Tu W; Potena L; Stepick-Biek P; Liu L; Dionis KY; Luikart H; Fearon WF; Holmes TH; Chin C; Cooke JP; Valantine HA; Mocarski ES; Lewis DB
Circulation; 2006 Oct; 114(15):1608-15. PubMed ID: 17015794
[TBL] [Abstract][Full Text] [Related]
10. Viral load, CMV-specific T-cell immune response and cytomegalovirus disease in solid organ transplant recipients at higher risk for cytomegalovirus infection during preemptive therapy.
Martín-Gandul C; Pérez-Romero P; Blanco-Lobo P; Benmarzouk-Hidalgo OJ; Sánchez M; Gentil MA; Bernal C; Sobrino JM; Rodríguez-Hernández MJ; Cordero E;
Transpl Int; 2014 Oct; 27(10):1060-8. PubMed ID: 24964364
[TBL] [Abstract][Full Text] [Related]
11. Levels of CMV specific CD4 T cells are dynamic and correlate with CMV viremia after allogeneic stem cell transplantation.
Widmann T; Sester U; Gärtner BC; Schubert J; Pfreundschuh M; Köhler H; Sester M
PLoS One; 2008; 3(11):e3634. PubMed ID: 18982061
[TBL] [Abstract][Full Text] [Related]
12. Evaluation and significance of cytomegalovirus-specific cellular immune response in lung transplant recipients.
Costa C; Astegiano S; Terlizzi ME; Sidoti F; Curtoni A; Solidoro P; Baldi S; Bergallo M; Cavallo R
Transplant Proc; 2011 May; 43(4):1159-61. PubMed ID: 21620077
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic utility of human cytomegalovirus-specific T-cell response monitoring in predicting viremia in pediatric allogeneic stem-cell transplant patients.
Abate D; Cesaro S; Cofano S; Fiscon M; Saldan A; Varotto S; Mengoli C; Pillon M; Calore E; Biasolo MA; Cusinato R; Barzon L; Messina C; Carli M; Palù G
Transplantation; 2012 Mar; 93(5):536-42. PubMed ID: 22314338
[TBL] [Abstract][Full Text] [Related]
14. [Impact of initial cytomegalovirus viral load on efficacy of preemptive therapy with ganciclovir in allogeneic stem cell transplant recipients].
Torre-Cisneros J; Caston-Osorio JJ; Martín C; Rivero A; Doblas A; Rojas R; Gómez P; Martínez F; Torres A
Enferm Infecc Microbiol Clin; 2010 Jan; 28(1):6-12. PubMed ID: 19409666
[TBL] [Abstract][Full Text] [Related]
15. Preemptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients.
Strippoli GF; Hodson EM; Jones C; Craig JC
Transplantation; 2006 Jan; 81(2):139-45. PubMed ID: 16436954
[TBL] [Abstract][Full Text] [Related]
16. Human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in adult allogeneic hematopoietic stem cell transplant recipients and immune control of viral infection.
Lilleri D; Fornara C; Chiesa A; Caldera D; Alessandrino EP; Gerna G
Haematologica; 2008 Feb; 93(2):248-56. PubMed ID: 18245650
[TBL] [Abstract][Full Text] [Related]
17. Relationship of reconstituted adaptive and innate cytomegalovirus (CMV)-specific immune responses with CMV viremia in hematopoietic stem cell transplant recipients.
Barron MA; Gao D; Springer KL; Patterson JA; Brunvand MW; McSweeney PA; Zeng C; Barón AE; Weinberg A
Clin Infect Dis; 2009 Dec; 49(12):1777-83. PubMed ID: 19911937
[TBL] [Abstract][Full Text] [Related]
18. Ex vivo monitoring of human cytomegalovirus-specific CD8(+) T-Cell responses using the QuantiFERON-CMV assay in allogeneic hematopoietic stem cell transplant recipients attending an Irish hospital.
Fleming T; Dunne J; Crowley B
J Med Virol; 2010 Mar; 82(3):433-40. PubMed ID: 20087937
[TBL] [Abstract][Full Text] [Related]
19. Effect of long-term prophylaxis in the development of cytomegalovirus-specific T-cell immunity in D+/R- solid organ transplant recipients.
San-Juan R; Navarro D; García-Reyne A; Montejo M; Muñoz P; Carratala J; Len O; Fortun J; Muñoz-Cobo B; Gimenez E; Eworo A; Sabe N; Meije Y; Martín-Davila P; Andres A; Delgado J; Jimenez C; Amat P; Fernández-Ruiz M; López-Medrano F; Lumbreras C; Aguado JM;
Transpl Infect Dis; 2015 Oct; 17(5):637-46. PubMed ID: 26134282
[TBL] [Abstract][Full Text] [Related]
20. Clinically-based determination of safe DNAemia cutoff levels for preemptive therapy or human cytomegalovirus infections in solid organ and hematopoietic stem cell transplant recipients.
Lilleri D; Baldanti F; Gatti M; Rovida F; Dossena L; De Grazia S; Torsellini M; Gerna G
J Med Virol; 2004 Jul; 73(3):412-8. PubMed ID: 15170637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
